DESCRIPTION: AST catalyzes a reversible transamination reaction between L-spartate and alpha-oxoglutarate. Pyridoxal-5-phosphate (P-5-P) is the prosthetic group of AST. The enzyme is localized in the cytoplasm and mitochondria of liver, heart muscle and skeletal muscle cells. The catalytic concentration of AST is measured in the serum of patients with heart and liver damage. DETERMINATION: Sample: Serum, plasma (heparin). Sample stability is 4 days if stored at 20-25°C, 7 days at 2°C to 8°C, 12 weeks at -20°C Measurement units: U/L Recommended method and/or procedure I: UV method (IFCC) AST catalyzes the transfer of amino groups from aspartate to alpha-ketoglutarate, resulting in glutamate and oxaloacetate. In the indicator reaction, oxaloacetate is reduced to malate under the influence of malate dehydrogenase, with the simultaneous oxidation of an equivalent amount of NADH to NAD+. The result is a decrease in absorbance, which is measured spectrophotometrically, and which is directly proportional to the catalytic activity of AST in the serum. LDH is added to quickly reduce any pyruvate present in the serum and thus eliminate its interference during the test. CLINICAL SIGNIFICANCE: 1) Physiological changes in the catalytic concentration of AST AST is increased in normal newborns. The level as in adults is reached by 7 years of age 2) Pathological changes in the catalytic concentration of AST A) Increased values
3.20€